WebAug 8, 2024 · The registrational Phase II study on the drug as a third-line treatment has started enrolling patients, with additional trials to be launched soon, including the Phase Ib DeLLphi-303 study, which will test tarlatamab with the standard of care in first-line SCLC and the Phase Ib study in de novo or treatment-emergent neuroendocrine prostate cancer. WebFeb 8, 2024 · Tarlatamab (formerly AMG 757), a first-in-class half-life extended BiTE ® molecule targeting delta-like ligand 3 (DLL3), is being studied in patients with relapsed/refractory small cell lung cancer (SCLC) after two or more prior lines of treatment.
Tarlatamab Demonstrates Preliminary Antitumor Efficacy in …
WebAt each treatment visit, all study participants will receive tarlatamab (study drug) by infusion (in a vein).. The study will be done in two parts: Part 1 will test two different dosage levels … WebDelta-like ligand 3 (DLL3) is overexpressed in most small cell lung cancer (SCLC). Tarlatamab (AMG 757), a half-life extended bispecific T cell engager (HLE BiTE®) molecule, binds DLL3 and CD3 leading to T cell-mediated tumor lysis. Interim phase 1 dose exploration data in SCLC (NCT03319940) show preliminary evidence for tarlatamab … texteditor下载
Phase 2 study of tarlatamab, a DLL3-targeting, half life–extended
WebTarlatamab is an investigational study drug that is being tested in clinical studies to see if it can help patients with either of two kinds of neuroendocrine cancer: small cell lung cancer (SCLC) or neuroendocrine prostate cancer (NEPC). Web比较 Tarlatamab 与标准化疗治疗复发性小细胞肺癌的研究 (DeLLphi-304) 小细胞肺癌 (SCLC) NCT05724199 招聘中 ... 一线 Tarlatamab 联合卡铂、依托泊苷和 PD-L1 抑制剂治疗广泛期小细胞肺癌 (ES-SCLC) 患者 ... WebJan 23, 2024 · Request PDF Tarlatamab, a First-In-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small Cell Lung Cancer: An Open-Label, Phase I Study Purpose … swot analysis threats for hotels